Most cases of Lewy body dementia (LBD) are not inherited in a straightforward, one-gene-from-a-parent fashion. But genetics play a larger role than many people realize. Researchers estimate that roughly 36% of what determines whether someone develops the condition can be attributed to genetic factors, a figure that puts LBD’s heritability in a similar range to other common neurodegenerative diseases. The picture involves a handful of rare mutations that can drive disease directly in families alongside dozens of common gene variants that each nudge risk up or down by a small amount.
How Much of the Risk Is Genetic
When scientists talk about heritability, they mean the share of variation in disease risk across a population that can be traced to DNA rather than to environment or chance. For LBD, that share has been estimated at about 36% using common genetic variants, meaning a substantial chunk of susceptibility has a genetic basis even though it does not follow a simple inheritance pattern.1PubMed Central. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions The remaining risk comes from environmental exposures, aging itself, and factors that researchers are still working to identify.
The genetic architecture is a mix of two things: rare variants with large effects and common variants with small effects.2Lancet Neurology. Advances in the genetics and pathology of Lewy body dementia Think of it like a card game where a few people are dealt an obviously bad hand (a rare, high-impact mutation), but most people accumulate risk through a combination of many individually minor cards. For the vast majority of people diagnosed with LBD, no single gene is “the cause.” Instead, a constellation of small-effect variants, interacting with non-genetic factors over a lifetime, tips the balance.
Rare Mutations That Can Drive Familial Cases
There are families where LBD clusters unmistakably across generations, and in some of these families researchers have pinpointed specific mutations. The most well-characterized involve the SNCA gene, which provides the blueprint for alpha-synuclein, the protein that clumps into Lewy bodies in the brain. Certain point mutations and, more dramatically, duplications or triplications of the entire SNCA gene region have been found in families with mixed presentations of parkinsonism and dementia resembling LBD.1PubMed Central. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions
Having three copies of SNCA (a duplication) tends to cause Parkinson’s disease or a milder Lewy body condition. Having four copies (a triplication) cranks up the production of the alpha-synuclein protein, leading to a more severe disease that starts earlier. These mutations are exceedingly rare in the general population, though, and even within families that carry them, the presentation can be wildly variable. One family member might develop dementia, another might show only Parkinson’s-type movement problems, and onset ages can differ by decades.1PubMed Central. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions Some SNCA duplications are not even fully penetrant, meaning a person can carry one and never develop symptoms at all.
In one well-studied kindred, the disease phenotype was highly variable: the index patient’s mother and an uncle presented with dementia, two younger-generation relatives showed only Parkinson’s features, and five others had a mix of both dementia and parkinsonism.3Brain. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder This variability within the same family, carrying the same mutation, is a recurring theme in LBD genetics and one reason the condition has been hard to classify neatly.
GBA Mutations and the Strongest Known Risk Factor
If SNCA mutations represent the rare, high-impact end of the spectrum, mutations in the GBA gene sit in a middle zone: uncommon enough that most people don’t carry them, but common enough to be the single largest identified genetic risk factor for Lewy body disorders. GBA provides instructions for an enzyme involved in breaking down certain fats inside cells. When the enzyme doesn’t work properly, it appears to disrupt the cellular cleanup processes that normally prevent alpha-synuclein from accumulating.
A meta-analysis pooling 29 studies found that GBA mutations were associated with an odds ratio of about 8.3 for developing DLB, meaning carriers were roughly eight times more likely to develop the disease than non-carriers.4PubMed. Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review Carriers also tended to have earlier symptom onset, more severe cognitive and motor problems, and more visual hallucinations. Individual studies have reported similar effect sizes. One case-control study found GBA mutations in about 7.6% of pure DLB cases compared with 0.8% of controls, yielding an odds ratio of 7.6.5PubMed Central. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
Those odds ratios sound alarming, but context matters. Despite the large individual effect, the frequency of GBA mutation carriers among people with LBD is still low in absolute terms. One research group estimated the population-attributable risk at only about 3% in people of European ancestry, meaning GBA mutations explain a very small slice of total LBD cases in the population even though they substantially raise risk for the individual who carries one.6JAMA Neurology. Glucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders Most people with a GBA mutation will never develop LBD; the mutation is a risk factor, not a guarantee.
APOE and the Web of Common Variants
Anyone familiar with Alzheimer’s disease will recognize APOE, the gene whose ε4 variant is the most well-known genetic risk factor for late-onset Alzheimer’s. It turns out APOE ε4 also increases the risk of LBD. A large genome-wide association study confirmed the link, reporting an odds ratio of about 2.4 for DLB associated with APOE variants.7The Lancet Neurology. Large-scale genome-wide association study of dementia with Lewy bodies That same study also confirmed associations with SNCA and GBA variants, identifying all three as genome-wide significant risk loci.
The mechanism behind APOE ε4’s involvement appears to go beyond its known effects on Alzheimer’s pathology. Research on autopsy-confirmed cases found that ε4 was associated with more severe Lewy body pathology even in brains with low Alzheimer’s-type changes, with an odds ratio of about 3.5 for diffuse Lewy body disease in that group.8PubMed Central. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology The researchers suggested that ε4 may promote the spread of Lewy body pathology through the brain rather than simply triggering it. This is a subtlety that clinical conversations often miss: APOE ε4 is not just an Alzheimer’s gene. It influences multiple neurodegenerative pathways.
Beyond APOE, GBA, and SNCA, genome-wide association studies have uncovered additional risk loci. One large multi-trait analysis identified 13 loci linked to LBD, including eight novel ones, with genes like TMEM175, CLU, MAPT, and FBXL19 reaching significance.9PubMed Central. Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer’s disease and Parkinson’s disease: a large-scale multi-trait association analysis Each of these individually contributes a small amount of risk. Their collective effect, combined with the bigger players, shapes overall susceptibility.
Does It Run in Families
Asking whether LBD is “hereditary” and asking whether it “runs in families” are related but not identical questions. Something can cluster in families without following a clear inheritance pattern, because family members share environment, lifestyle, and a pool of common-variant risk genes that individually do very little.
A study comparing siblings of people diagnosed with DLB to siblings of Alzheimer’s patients found that the DLB siblings had about twice the odds of developing probable DLB themselves, with an odds ratio of 2.29.10JAMA Neurology. Familial Aggregation of Dementia With Lewy Bodies They also had higher odds of experiencing visual hallucinations, a hallmark symptom. Those numbers suggest a real familial component, but the absolute risk for any given sibling remained low. Having a sibling with DLB does not make it likely you will develop it; it makes it somewhat more likely compared to the general population.
Most people with LBD have no affected close relatives. The familial aggregation data and the heritability estimate are population-level statistics. For the individual asking, “My parent had Lewy body dementia, am I going to get it?” the honest answer is that the risk is modestly elevated but far from certain. No one should walk away from a family diagnosis assuming they are destined for the same outcome.
Epigenetic Factors and Why Genes Aren’t the Whole Story
Even when we account for all the known genetic variants, the majority of LBD risk remains unexplained. Part of the gap may be filled by epigenetics, which refers to chemical modifications that alter how genes are read without changing the DNA sequence itself. Environmental exposures, aging, diet, and other factors can add or remove these chemical tags over time, turning genes up or down.
A growing body of research suggests that epigenetic mechanisms act as mediators between the environment and gene expression in LBD. The combination of genetic variation and epigenetic changes, particularly DNA methylation and histone modifications, appears to influence disease susceptibility and course.11PubMed Central. Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy One epigenome-wide study found seven differentially methylated sites and three broader regions in the DNA of confirmed DLB cases compared with controls, suggesting a distinct methylation signature associated with the disease.12Communications Biology. Differential methylation analysis in neuropathologically confirmed dementia with Lewy bodies
This is still early-stage science, but it has a practical implication: even if you carry risk-increasing gene variants, the way those genes behave may be shaped by factors that accumulate over your lifetime. Epigenetics helps explain why identical twins, who share virtually all their DNA, do not always develop the same neurodegenerative diseases. It also opens the door to the possibility that some risk could be modifiable, though no specific epigenetic intervention for LBD exists yet.
Where LBD Overlaps Genetically with Alzheimer’s and Parkinson’s
LBD sits at a genetic crossroads between Alzheimer’s disease and Parkinson’s disease, sharing risk loci with both. APOE is a major Alzheimer’s risk gene that also influences LBD. SNCA and GBA are well-established Parkinson’s risk genes that also influence LBD. And the overlap goes deeper: two genetic loci, TMEM175 and HLA, showed shared associations across three different neurodegenerative disorders, including LBD, Alzheimer’s, and Parkinson’s.13PubMed. The genetic overlap between Alzheimer’s disease, amyotrophic lateral sclerosis, Lewy body dementia, and Parkinson’s disease
This genetic overlap mirrors what clinicians see in practice. LBD often co-occurs with Alzheimer’s-type brain changes. Many Parkinson’s patients develop dementia that looks very much like DLB. And the boundaries between these diagnoses can be blurry enough that the same patient might receive different labels depending on which symptoms appeared first. The genetics reinforce the idea that these are not entirely separate diseases but rather related conditions sitting on a spectrum, with shared underlying biology involving protein clearance, inflammation, and lipid processing in the brain.14PubMed Central. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders
For families, this has a counterintuitive consequence. A family history of Parkinson’s disease or Alzheimer’s disease, not just LBD specifically, might carry some relevance when thinking about LBD risk, because the genetic underpinnings partially overlap. Researchers studying one genome-wide association dataset noted that GBA, APOE, and SNCA are linked through shared cellular pathways involving the breakdown and recycling of proteins and fats inside neurons.15Scientific Reports. GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study
What About LRRK2, the “Parkinson’s Gene”
LRRK2 mutations are one of the most common genetic causes of familial Parkinson’s disease, so a natural question is whether they also contribute to LBD. The answer, based on current evidence, is that their role in LBD appears minimal. When researchers screened large series of DLB cases for pathogenic LRRK2 variants, they found very few carriers. In one study, only one clinical DLB patient carried the common G2019S mutation, and another carrier initially classified as DLB turned out on closer review to have Parkinson’s disease with dementia instead.16PubMed Central. LRRK2 variation and dementia with Lewy bodies
Interestingly, LRRK2 protein does show up in Lewy bodies when researchers stain brain tissue with antibodies targeting it, confirming it is physically present in the hallmark pathology of both Parkinson’s and DLB.17PubMed Central. LRRK2 in Parkinson’s disease and dementia with Lewy bodies But being present in the pathology is different from causing it. For now, LRRK2 mutations do not appear to be a meaningful driver of DLB, which is one point where the genetics of LBD and Parkinson’s diverge despite their many similarities.
Genetic Testing in Practice
Given everything above, you might wonder whether genetic testing is useful for someone worried about LBD risk or already showing symptoms. The current reality is sobering. A survey of U.S. experts in DLB found that most do not routinely order genetic testing in clinical care.18PubMed Central. Biomarker Use for Dementia with Lewy Body Diagnosis: Survey of U.S. Experts Those who do use it tend to reserve it for patients with strong family histories, particularly when dementia starts at a young age. The most commonly cited reasons for not ordering it were that the results rarely change clinical management and that logistical barriers like cost, insurance coverage, and lack of genetic counseling access make it impractical.
This is not an oversight by the medical community. It reflects the fact that no single genetic test can confirm or rule out LBD for most patients. The rare high-impact mutations are too uncommon to screen for routinely, and the common risk variants individually carry too little predictive power to be clinically actionable. A positive result for, say, APOE ε4 tells you that your risk of several neurodegenerative diseases is modestly elevated, but it doesn’t tell you whether you will develop any of them, and it doesn’t change the treatment you’d receive.
For families with multiple members affected by Lewy body dementia or related conditions at relatively young ages, genetic testing may be worth discussing, ideally with a genetic counselor who specializes in neurodegeneration. In those rare pedigrees, identifying a specific mutation can be informative for family planning discussions and can connect families with research studies testing targeted therapies. For the far more common situation of a single affected relative diagnosed later in life, current genetic testing has little practical yield.19PubMed. Genetic testing in dementia-A medical genetics perspective
REM Sleep Behavior Disorder as an Early Clue
One area where genetics and early detection intersect is REM sleep behavior disorder, or RBD, in which people physically act out vivid dreams during sleep. RBD is one of the strongest known predictors of future Lewy body dementia or Parkinson’s disease, with a high proportion of people diagnosed with RBD eventually converting to one of these conditions over the following decade or two.
Recent research has begun to trace the genetic overlap between RBD and LBD. A study examining shared biological pathways found that eight pathways derived from LBD genome-wide association data showed positive associations with RBD susceptibility, and these were the only pathways to survive stringent correction for multiple testing.20PubMed Central. Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders This genetic connection supports the clinical observation that RBD and LBD are biologically linked, not just coincidentally co-occurring. For someone diagnosed with RBD, understanding its genetic ties to LBD can frame conversations about monitoring and early intervention with their physician, even though no preventive treatment currently exists.
Biological Pathways Under the Genetics
Across the various genes implicated in LBD, a common set of cellular problems keeps surfacing. The monogenic disorders associated with Lewy body formation converge on disruptions in lipid metabolism, autophagy (the cell’s waste-recycling system), and mitochondrial function.14PubMed Central. Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders GBA mutations impair lysosomal enzyme activity, which leads to a buildup of fatty substrates and hinders the cell’s ability to clear misfolded alpha-synuclein. SNCA mutations either produce too much alpha-synuclein or produce a version prone to clumping. APOE ε4 is less efficient than its ε3 counterpart at facilitating the breakdown and removal of certain proteins.
These pathways are not independent. Lysosomal dysfunction worsened by GBA deficiency can accelerate alpha-synuclein aggregation, and the resulting protein clumps can further impair mitochondria, creating a vicious cycle. The fact that multiple genetic entry points funnel into the same downstream bottleneck helps explain why LBD’s genetic architecture is so diverse: many different genetic disruptions can push the same cellular machinery toward failure. It also suggests that therapies targeting these shared bottlenecks, particularly lysosomal function and alpha-synuclein clearance, could be beneficial regardless of which specific gene variant a person carries. Several clinical trials are exploring exactly this approach, though none has yet produced an approved treatment specifically for LBD.